TD Cowen Reiterates Buy Rating on Neogenomics (NEO): reimbursements 'could drive '26 revenue growth 3-4% higher'
Tweet Send to a Friend
TD Cowen analyst Dan Brennan reiterated a Buy rating and $16.00 price target on Neogenomics (NASDAQ: NEO)The analyst commented, "This ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
